Vertex Pharmaceuticals Incorporated — Q2 2020 Form 10-Q
Business context and period: Unaudited results for the three and six months ended June 30, 2020, compared with the same 2019 periods. Vertex’s business centers on cystic fibrosis (CF) medicines, led by TRIKAFTA, alongside a developing pipeline in genetic and cell therapies and other disease areas. Amounts below are in U.S. dollars; financial statement figures are in millions except per-share data.
Financial performance
| Metric | Q2 2020 | Q2 2019 | H1 2020 | H1 2019 |
|---|---|---|---|---|
| Revenue | $1,524.5 | $941.3 | $3,039.6 | $1,799.7 |
| Operating income | $718.0 | $270.0 | $1,438.3 | $546.8 |
| Net income | $837.3 | $267.4 | $1,440.0 | $536.1 |
| Diluted EPS | $3.18 | $1.03 | $5.46 | $2.06 |
| Cash from operations | — | $1,854.2 | $788.5 |
Margins: Q2 operating margin was approximately 47.1%, versus 28.7% a year earlier; H1 was approximately 47.3%, versus 30.4%. Cost of sales was 12% of product revenue in Q2 (14% in Q2 2019) and 11% in H1 (13% in H1 2019).
Revenue mix: Q2 TRIKAFTA revenue was $917.7 million; SYMDEKO/SYMKEVI $171.7 million; ORKAMBI $232.0 million; and KALYDECO $203.1 million. H1 TRIKAFTA revenue was $1,812.9 million. Product revenue growth was driven primarily by the U.S. launch of TRIKAFTA in late 2019. Revenue from the other CF products declined as U.S. patients switched to TRIKAFTA, partly offset by ex-U.S. growth.
Cash, liquidity and obligations: At June 30, cash and cash equivalents were $4,831.3 million and marketable securities were $619.4 million, totaling $5,450.8 million, up $1,642.5 million from year-end 2019. Working capital was $4,895.7 million. H1 investing cash flow was positive $103.6 million and financing cash flow was negative $239.4 million; capital expenditures were $37.3 million. Total liabilities were $2,697.1 million, including $522.1 million of long-term finance lease liabilities. The company had no borrowings under its $500 million revolving credit facility and reported compliance with its covenants.
Material changes and notable items
- Revenue rose 62% in Q2 and 69% in H1 year over year. Net income rose 213% in Q2 and 169% in H1.
- Operating expenses increased 20% in Q2 and 28% in H1, reflecting higher cost of sales, research and development, and SG&A. H1 R&D was $869.5 million, up 21%; H1 SG&A was $374.1 million, up 23%.
- Other income, net was $116.4 million in Q2 and $55.2 million in H1, primarily reflecting fair-value changes and sales of strategic equity investments. Vertex reported $85.5 million of Q2 unrealized gains on equity securities held at quarter-end; these investment gains can be volatile.
- Q2 income tax benefit was $12.5 million, versus tax expense of $59.7 million in Q2 2019. The 2020 tax rate benefited from a $187.0 million deferred tax benefit tied to an intra-entity transfer of intellectual property to the U.K., as well as other discrete tax benefits. The H1 tax provision was $42.3 million.
- H1 included $300.0 million of share repurchases; $164.0 million remained available under the program at June 30. No shares were repurchased during Q2.
Outlook, commentary and risks
- Management said COVID-19 had not affected product demand or supply to date and expected existing cash, securities and product cash flows to fund operations for at least the next 12 months. It nevertheless cautioned that the pandemic could affect payor mix, pricing, clinical development and third parties; the ultimate impact remained uncertain.
- Vertex reported that most U.S. patients eligible for TRIKAFTA had initiated treatment. The European Medicines Agency committee issued a positive opinion for the triple combination in June; European Commission approval was still pending. The company expected data from a trial in children ages 6–11 in H2 2020 and, if positive, planned an FDA filing in Q4 2020.
- Management expected additional CTX001 patient data in H2 2020. Some clinical trials had experienced temporary COVID-related pauses, though enrollment and dosing had resumed. VX-814 trial data were expected at year-end 2020 or in Q1 2021; a Phase 2 trial of VX-864 began in July.
- No numerical revenue or earnings guidance is provided in the supplied filing text. Management noted that H1 revenue benefited from patient inventory levels and compliance and persistence among recent TRIKAFTA initiators, factors that may not recur.
- Other risks include clinical and regulatory uncertainty, reimbursement and market access, strategic-investment volatility, foreign-exchange exposure, and potential milestone payments. Vertex expected to repay a portion of amounts collected through French ORKAMBI early-access programs in H2 2020. It reported no material legal proceedings and no material accrued contingent liabilities.
Important facts for investors to verify
- Whether TRIKAFTA/KAFTRIO approvals, label expansions and reimbursement access progress on the anticipated timelines, and how quickly eligible patients adopt treatment.
- Whether revenue growth remains strong as U.S. patients switch from older CF products and as one-time inventory or patient-persistence effects normalize.
- How much reported earnings reflect recurring operations versus equity-investment gains and the discrete tax benefit from the U.K. IP transfer.
- COVID-19’s continuing effects on clinical trials, supply, reimbursement, pricing and third-party operations.
- Future R&D spending, pipeline results, Exonics contingent consideration, and the timing of French government repayments and remaining share repurchases.